Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bushen Ningxin Decoction is a traditional Chinese medicine (TCM) herbal formula composed of eight herbs: dried Rehmannia root (Rehmanniae Radix Praeparata), common Anemarrhena rhizome, bark of Chinese Corktree, Barbary Wolfberry fruit, Chinese Dodder seed, Shorthorned Epimedium herb, Spina date seed and Oriental water plantain rhizome. It has been used for hundreds of years to prevent and treat menopause- and aging-associated disorders such as postmenopausal osteoporosis. The decoction acts by inhibiting osteoclastogenesis—primarily through abrogation of RANKL-induced NFATc1 and NF-κB signaling pathways via selective activation of estrogen receptor α (ERα). It also increases serum dehydroepiandrosterone (DHEA) levels without affecting estradiol concentrations. Additionally, it modulates the immune environment by increasing CTLA-4+ regulatory T cells and promoting apoptosis in CD4+ T cells while regulating the RANKL/OPG balance in these cells[1][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Bushen Ningxin Decoction.